Core Viewpoint - The ChiNext Medical Index (970082) closed at 3876.07 points on February 3, with a gain of 2.37% and a trading volume of 13.236 billion yuan, indicating positive market sentiment in the medical sector [1]. Group 1: Index Performance - The ChiNext Medical Index saw 49 constituent stocks rise, with NuoSiGe leading the gains at 8.76% [1]. - The index's turnover rate was 1.71%, reflecting moderate trading activity [1]. Group 2: Top Constituents - The top ten constituents of the ChiNext Medical Index include: - YuanEr Eye Hospital (sz300015) with a weight of 9.18% and a latest price of 11.04 yuan, up 1.28% [1]. - MaiRui Medical (sz300760) with a weight of 8.95% and a latest price of 188.15 yuan, up 0.56% [1]. - TaiGe Medical (sz300347) with a weight of 8.52% and a latest price of 63.20 yuan, up 4.97% [1]. - KangLong HuaCheng (sz300759) with a weight of 7.18% and a latest price of 29.61 yuan, up 2.10% [1]. - LePu Medical (sz300003) with a weight of 4.96% and a latest price of 17.83 yuan, up 1.89% [1]. - New Industry (sz300832) with a weight of 4.73% and a latest price of 54.50 yuan, up 2.60% [1]. - AiMeiKe (sz300896) with a weight of 4.49% and a latest price of 147.57 yuan, up 4.56% [1]. - YingKe Medical (sz300677) with a weight of 4.14% and a latest price of 40.55 yuan, up 1.38% [1]. - FuRui Medical (sz300049) with a weight of 3.55% and a latest price of 67.33 yuan, up 1.45% [1]. - HuaDa Gene (sz300676) with a weight of 3.15% and a latest price of 50.30 yuan, up 2.57% [1]. Group 3: Capital Flow - The net inflow of main funds into the ChiNext Medical Index constituents totaled 145 million yuan, while retail investors experienced a net outflow of 106 million yuan [1]. - The detailed capital flow indicates that TaiGe Medical had a main fund net inflow of 10.514 million yuan, while retail investors had a net outflow of 18.28% [2].

证券日报网讯 2月3日，华大基因发布公告称，近日，公司于 2026 年 1 月 27 日召开第四届董事会第八 次会议，审议通过了《关于聘任公司总经理暨变更法定代表人的议案》，公司董事会同意聘任侯勇先生 担任公司总经理，任期自公司第四届董事会第八次会议审议通过之日起至第四届董事会任期届满之日 止。同时根据《公司章程》第八条的规定，"代表公司执行公司事务的董事或者总经理为公司的法定代 表人"，侯勇先生担任公司总经理之日起同时担任公司法定代表人。公司完成了法定代表人、总经理变 更的工商登记备案手续，取得了深圳市市场监督管理局换发的《营业执照》及出具的《登记通知书》 《增、减、补、换发证照通知书》。 （编辑 楚丽君） ...

Group 1 - The tumor gene testing industry is experiencing rapid development, with significant international transactions and domestic regulatory reforms since Q4 2025 [1] - Leading U.S. tumor gene testing companies have shown strong stock price growth, with Natera, Exact Science, Guardant, and Grail achieving annual stock price increases of 52%, 78%, 221%, and 464% respectively [1] - The tumor gene testing sector maintains high growth potential, covering early screening, auxiliary diagnosis, companion diagnosis, efficacy monitoring, and recurrence prediction in precision treatment [1] Group 2 - Exact Sciences is a leading company in colorectal cancer screening, with a revenue guidance of $3.22 to $3.235 billion for 2025, representing a growth of 16.7% to 17.2% [2] - The accessible market for colorectal cancer screening in the U.S. is approximately 120 million individuals aged 45-85, with about 70 million already screened [2] - Future growth drivers for Exact Sciences include rescreening, addressing care gaps, pricing increases for Cologuard Plus, targeting younger demographics, and a strong commercialization strategy [2] Group 3 - Natera is a leader in minimal residual disease (MRD) testing, with projected revenue of approximately $2.3 billion for 2025 [3] - The core MRD product, Signatera, achieved over 200,000 samples in Q3 2025, marking a 54% year-over-year increase [3] - Natera's Signatera is one of the most scientifically validated MRD testing products, supported by over 125 peer-reviewed publications across more than 30 tumor types [3] Group 4 - The tumor gene testing industry is in a growth phase, with significant international transactions and domestic regulatory innovations [4] - Key domestic players include Adicon Biotech, which presented innovative lung cancer MRD products, and BGI Genomics, which is expanding into various cancer early screening and monitoring scenarios [4] - Mirxes-B launched China's first early screening product for gastric cancer, while Burning Rock Medical's Lungwei has achieved excellent results in multiple cancer MRD clinical trials [4]

证券代码：300676 证券简称：华大基因 公告编号：2026-010 深圳华大基因股份有限公司 关于完成法定代表人、总经理工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、情况概述 深圳华大基因股份有限公司（以下简称公司）于 2026 年 1 月 27 日召开第四届董事 会第八次会议，审议通过了《关于聘任公司总经理暨变更法定代表人的议案》，公司董 事会同意聘任侯勇先生担任公司总经理，任期自公司第四届董事会第八次会议审议通过 之日起至第四届董事会任期届满之日止。同时根据《公司章程》第八条的规定，"代表 公司执行公司事务的董事或者总经理为公司的法定代表人"，侯勇先生担任公司总经理 之日起同时担任公司法定代表人。具体内容详见公司于 2026 年 1 月 28 日披露于巨潮资 讯网（http://www.cninfo.com.cn）的《关于总经理辞任暨变更总经理及法定代表人的公 告》（公告编号：2026-008）。 二、进展情况 | 公司名称 | 深圳华大基因股份有限公司 | | --- | --- | | 类型 | 其他股份有限公司（上市） ...

Group 1 - The core viewpoint is that AI has penetrated the entire healthcare industry chain, with significant growth driven by technological advancements and policy support [1][2] - AI applications in healthcare vary in maturity, with smart healthcare, particularly in medical imaging, being one of the most developed areas [2] - The global market for AI solutions in healthcare is projected to grow from $13.7 billion in 2022 to $155.3 billion by 2030, with a CAGR of 35.5% [2] Group 2 - Recent policies from multiple government departments are promoting the application of AI in healthcare, with the National Medical Products Administration prioritizing "AI medical devices" as a key development area [2] - AI medical products are being rapidly implemented, with companies like Mindray and United Imaging set to release advanced AI models in the coming years [4] - The performance of the Shenwan Pharmaceutical Index has been mixed, with a recent decline of 3.68%, underperforming the CSI 300 Index [3]

Investment Rating - The report maintains an "Outperform" rating for the tumor gene testing industry [1] Core Insights - The tumor gene testing industry is on a fast development track, with significant international transactions and domestic regulatory innovations occurring since Q4 2025. The market is expected to expand significantly as applications for tumor MRD and multi-cancer early screening mature [2][6] - Exact Sciences is a leading company in colorectal cancer screening, projecting revenues of $3.22 to $3.235 billion for 2025, representing a growth of 16.7% to 17.2%. The company aims for a compound annual growth rate (CAGR) of 15% from 2022 to 2027 [2][18] - Natera is recognized as a leader in minimal residual disease (MRD) testing, with its core product, Signatera, achieving a sample volume of over 200,000 in Q3 2025, reflecting a year-on-year growth of 54% [2][68] - The report emphasizes the importance of monitoring technological advancements and the positioning of leading companies in the tumor gene testing sector [2] Summary by Sections 1. Tumor Gene Testing Industry Overview - The tumor gene testing sector is experiencing rapid growth, with significant stock price increases for leading companies such as Natera (52%), Exact Science (78%), Guardant (221%), and Grail (464%) in 2025 [2][6] - The market is projected to expand significantly, with potential market sizes for early screening (multi-cancer MCED and colorectal cancer) estimated at $40-50 billion, MRD at $15-20 billion, and companion diagnostics/treatment guidance at $3-5 billion [11][12] 2. Exact Sciences: Colorectal Cancer Screening Leader - Exact Sciences has established a robust medical ecosystem with a testing capacity exceeding 10 million annually. Its core product, Cologuard, has a brand recognition rate of over 90% [18] - The company anticipates maintaining a revenue growth rate of 15% and aims for an adjusted EBITDA margin exceeding 20% by 2027 [18][24] - Cologuard's future growth drivers include rescreening, addressing care gaps, pricing increases for the Plus version, and expanding into younger demographics [45][48] 3. Natera: Leader in MRD Testing - Natera's MRD product, Signatera, is pivotal in assessing treatment efficacy and guiding clinical decisions, with a significant focus on ctDNA mutation detection [2][68] - The company is expanding its presence in women's health and organ health, while also entering the colorectal cancer screening market [2][68] 4. Domestic Company Landscape and Investment Recommendations - The report highlights the innovative developments from domestic companies such as Aide Biology, BGI, and Mirxes, which are making strides in lung cancer MRD products and multi-cancer early screening [2] - The report suggests monitoring the technological advancements and market positioning of these domestic leaders as the industry evolves [2]

Core Viewpoint - The article discusses the innovative "Gengram" module introduced by the Genos team, which enhances genomic models by integrating an external memory mechanism to improve efficiency and performance in genomic tasks [2][10]. Group 1: Gengram Module Introduction - The Gengram module aims to address the limitations of existing genomic models that only process DNA sequences at the single-base level, which is inefficient for understanding biological functions [8][10]. - By utilizing a pre-built hash dictionary of common short sequences, Gengram allows models to retrieve biological knowledge directly, reducing the need for extensive computation [10][12]. Group 2: Performance Improvements - Models equipped with Gengram have achieved state-of-the-art (SOTA) results, with a 16.1% increase in AUC for splice site recognition tasks [6][18]. - Gengram is a lightweight plugin, with only about 20 million parameters, significantly enhancing model capabilities without requiring extensive training data [18][21]. Group 3: Biological Insights - The design of Gengram allows AI to consider the three-dimensional structure of DNA while processing one-dimensional sequences, improving its understanding of biological interactions [14][15]. - The optimal performance of Gengram was observed with a window size of 21 base pairs, which corresponds to the spatial arrangement of DNA [13][14]. Group 4: Team and Collaboration - The Genos team combines expertise from BGI's life sciences research and computational capabilities from Zhejiang Lab, representing a strategic collaboration in the AI for Science domain [20][21]. - The success of Gengram highlights the potential of aligning AI with biological logic to advance the understanding of genomic data [21].

专题：为中国经济点赞——企业家之夜2025盛典 "为中国经济点赞——企业家之夜"于1月29日在北京举行。浙江强脑科技有限公司创始人兼CEO韩璧丞 出席接受致敬。全国工商联纺织服装业商会理事长，波司登品牌创始人、集团董事局主席兼总裁高德 康，华大集团CEO尹烨为其见证荣誉。 随后，强脑科技仿生手受益人、假肢售后负责人古月与韩璧丞共同展示了前沿脑机接口技术如何深刻改 变残障人士的生活。 古月分享了他的经历：2018年因意外失去左手。2019年，其表哥在重庆一场展会上了解到强脑科技的智 能假肢后，为他取得了联系方式，由此结缘。首次体验该技术时，他深感震撼。 专题：为中国经济点赞——企业家之夜2025盛典 "为中国经济点赞——企业家之夜"于1月29日在北京举行。浙江强脑科技有限公司创始人兼CEO韩璧丞 出席接受致敬。全国工商联纺织服装业商会理事长，波司登品牌创始人、集团董事局主席兼总裁高德 康，华大集团CEO尹烨为其见证荣誉。 活动现场，古月展示了其佩戴的智能仿生手。他介绍，这只手无需手术植入，可通过直观的意念进行操 控，感觉"仿佛我的左手重新回来了"。随后，他先后完成了抓举10公斤及5公斤哑铃、弹钢琴、远程操 控仿 ...

Core Insights - The event "Praise for China's Economy - Entrepreneur Night" was held on January 29 in Beijing, where Han Bicheng, founder and CEO of Zhejiang Qiangnao Technology Co., was honored [1][5] Company Overview - Qiangnao Technology focuses on brain-computer interface technology, aiming to bridge the gap between advanced technology and everyday life [3][7] - The company targets approximately 5 million individuals with physical disabilities in China, many of whom have become socially isolated due to the loss of limbs [3][7] Product Development - Qiangnao Technology has developed a neural-controlled prosthetic that has successfully helped users regain functionality, exemplified by a user who, after 27 years, was able to grasp a cup [3][7] - The company has also created a sleep aid product after five years of development, which has reportedly improved sleep for users who have struggled for decades [3][7] Future Vision - The company envisions using brain-computer interface technology to assist more individuals, including helping disabled individuals walk again, enabling children with autism to speak, and aiding those with Alzheimer's to delay memory loss [3][7][8] - Han Bicheng emphasized that the goal is not to create opportunities but to restore daily life interrupted by fate [4][8]

Group 1 - The event "Praise for China's Economy - Entrepreneur Night" was held on January 29 in Beijing, honoring the founder and CEO of Zhejiang Qiangnao Technology Co., Ltd., Han Bicheng [1][2] - Notable attendees included Gao Dekang, Chairman and President of Bosideng Group, and Yin Ye, CEO of BGI Group, who witnessed the honor [1][2] Group 2 - Yin Ye emphasized the emotional impact of technology, highlighting examples of individuals with disabilities who can now engage in activities like dancing and playing piano through advanced prosthetics [3][5] - Han Bicheng stated that Qiangnao Technology aims to use cutting-edge technology, specifically thought control, to assist approximately 5 million people with limb disabilities in China, helping them reintegrate into society and work [3][5]